Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model

Safety of Pluristem's PLX Cells Demonstrated in Pre-Clinical Pregnancy Model

Important Milestone Advances Pluristem's Clinical Development Program for the
Treatment of Preeclampsia Using PLX-PAD Cells

HAIFA, Israel, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that its PLacental eXpanded (PLX) cells proved to
be safe in an animal study assessing maternal and fetal toxicity. The study
was conducted at the Charles River Laboratories, one of the world's leading
contract research organizations. The results showed that the intramuscular
administration of PLX-PAD cells to pregnant rats did not result in any
maternal or fetal toxicity. Pluristem will pursue the clinical development of
PLX-PAD cells for the indication of preeclampsia based on these results and
earlier evidence that the cells were efficacious in preeclamptic animal
models.

"Pluristem is extremely pleased with the demonstrated safety of our PLX-PAD
cells in pre-clinical models of pregnancy," said Zami Aberman, Chairman and
CEO of Pluristem. "This study, together with the work performed by Dr. Brett
Mitchell from Texas A&M College of Medicine,suggesting that our PLX-PAD cells
are efficacious in preeclamptic animal models, is an important milestone
towards our goal of initiating clinical trials for preeclampsia."

In the study, forty-four pregnant female rats were injected intramuscularly
with either PLX-PAD at a dosage of 10 million cells (n=22) or cell-free
placebo (n=22), on gestational day 13. Throughout the study the pregnant
animals were monitored for viability status, body weight and food consumption.
On gestational day 21, female rats were examined for ovarian and uterine
contents and abnormalities in dams and pups. Charles River's report concluded
that the IM injection of PLX-PAD cells in pregnant rats did not result in any
maternal or fetal developmental toxicity.

About Preeclampsia

Preeclampsia is one of the most common medical complications of pregnancy, and
one of the leading causes of premature births, stillbirths and early neonatal
and maternal deaths. If left untreated, it can progress to eclampsia, the
life-threatening occurrence of seizures during pregnancy. The only known
treatment for preeclampsia is abortion or delivery. The disease occurs in
previously healthy women after their 20th week of pregnancy, and signs include
high blood pressure and significant amounts of protein in the urine. According
to the World Health Organization, preeclampsia occurs in approximately 6–8% of
pregnancies worldwide. It is estimated that preeclampsia costs the global
health care system $3 billion annually.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D expansion technology and are an
"off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the results
of testing our PLX cells in preclinical pregnancy animal model, as well as our
plans to pursue clinical trial for the indication of preeclampsia, we are
using forward-looking statements. These forward-looking statements and their
implications are based on the current expectations of the management of
Pluristem only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.